Blog
About
Press
FAQ
Resources
Education
Sales
Cost Calculator
Contact

Blog
About
Press
FAQ
Resources
Education
Sales
Cost Calculator
Contact

Search

ChallengeRetained Blood Syndrome
SolutionPleuraFlow® ACT
MissionA New Standard

Press 2007

Cleveland Clinic & Medical Device Innovations, LLC, Form Clear Catheter Solutions LLC

by James Herlofsky

Oregon incubator, Clinic form joint ventures

by James Herlofsky

Recent Press

ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan
ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons
Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery
Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System
ClearFlow, Inc. Announces Positive US Clinical Trial Results

Archives

2018
2017
2016
2015
2014
2013
2012
2011
2007

Press Contact:

Paul Williams
MediaLine Communications
(949) 916-6880
paul@medialinecommunications.com

or

James Herlofsky, Marketing Manager
ClearFlow, Inc.
(310) 569-5604
jherlofsky@clearflow.com

ChallengeRetained Blood Syndrome
SolutionPleuraFlow® ACT
MissionA New Standard

Blog
About
Press
FAQ
Resources
Education
Sales
Cost Calculator
Contact

Clinical References| Terms of Use| PleuraFlow ACT System Indications of Use|

PleuraFlow® ACT® is not indicated as a therapeutic device.

ClearFlow’s PleuraFlow® Active Clearance Technology® and many of its features are protected by a comprehensive family of both US and foreign patents and patent applications in major markets throughout the world, including Canada, Australia and the European Community. In the United States, PleuraFlow® products are protected by US Patent Nos. 7,854,728, 7,951,243, 8,246,752, 8,048,233, 8,388,759, 8,702,662 and 8,951,355. The PleuraFlow® product is the first device of its kind to effectively and reproducibly clear obstructing material from chest tubes without compromising the sterile field, and thus patient recovery. It is the only FDA 510(k) cleared device of its kind for this indication. ClearFlow’s patent portfolio has been tailored not only to protect this product, but also to provide protection around this new market segment thus presenting a barrier to entry for competing products.

Website by Bloom Creative